Multiple Recurrent Mutations Linked to Worse Outcome in Relapsed CLL

Share this content:
Concurrent gene mutations in patients with relapsed/refractory chronic lymphocytic leukemia are linked to a worse outcome.
Concurrent gene mutations in patients with relapsed/refractory chronic lymphocytic leukemia are linked to a worse outcome.

Concurrent gene mutations in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) are linked to a worse outcome, according to an article published online ahead of print in Blood.1

Certain mutations such as TP53, NOTCH1, and SF3B1 impair the prognosis of patients with CLL receiving frontline therapy.

However the clinical implications of these mutations in the relapsed/refractory setting were unclear. Therefore investigators used targeted next-generation sequencing of the genomes of 114 patients with relapsed/refractory CLL.

The investigators performed clustering according to the number of mutated genes and the number of recurrence of gene mutations.

RELATED: Large-Scale Genomic Analysis Gives New Insights Into the Chronology, Evolution of CLL

Results revealed that the number of genes affected by mutation was ≥ 2, 1, and 0 in 43 (38%) patients, 49 (43%), and 22 (19%), respectively. 

Recurrent combinations of 2 or more mutations of TP53, SF3B1, and ATM occurred in 22 (19%) of patients. This profile was linked to a decreased progression-free survival (12 months vs 22.5 months in the other patients; P = .003).

Reference

  1. Guièze R, Robbe P, Clifford R, et al. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL [published online ahead of print October 29, 2015]. Blood. doi: 10.1182/blood-2015-05-647578.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters